Safety of disease-modifying therapies in multiple sclerosis: real-world data from the Austrian MS Treatment Registry (AMSTR).

ABSTRACT:

Background

In the therapeutic landscape of multiple sclerosis (MS), more than a dozen disease-modifying therapies (DMT) are currently available. In Austria, only certified MS centers are authorized to prescribe DMT and are obliged to enter patient data into the Austrian MS Therapy Registry (AMSTR). Here, we report the safety profiles of different DMT documented in this registry.

Methods

Adverse events (AE) data from the AMSTR, collected at least biannually from August 2006 to July 2025, were extracted. AE were classified by system organ classes according to the Medical Dictionary for Regulatory Activities.

Results

This analysis included 7913 patients (67.7% female, median age 37 years [IQ 29-45]), with the majority receiving dimethyl fumarate (2572/7913, 32.5%), follo

SUBMITTER: Monschein T 

PROVIDER: S-EPMC12630275 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature